Sage Therapeutics (NASDAQ:SAGE) traded lower for the third straight session on Tuesday after Bank of America moved the ...

As Sage Therapeutics Inc. contemplates its path forward after rejecting a buyout offer from Biogen, its top executive ...

BofA resumed coverage of Sage Therapeutics (SAGE) with an Underperform rating and $5 price target. The impact of Biogen’s (BIIB) unsolicited ...

Sage Therapeutics’ board of directors has turned back partner Biogen’s opportunitistic attempt at a takeover, unanimously rejecting a $469 million offer from Biogen it said “significantly ...

As it waits for its Alzheimer’s drug verdict, Biogen stumps up $1.5bn-plus upfront for rights to Sage drugs zuranolone for depression and SAGE-324 for essential tremor ...

Last year, the first phase 3 trial of Sage Therapeutics and Biogen's antidepressant hopeful zuranolone hit its efficacy targets, but raised doubts about the durability of the response. Now ...

Sage Therapeutics has rejected a buyout bid from partner Biogen and launched a review of strategic alternatives. Sage on Monday said its board determined that Biogen's $7.22-a-share proposal ...

Biogen's strategic missteps, including the failed Sage Therapeutics acquisition, underscore a lack of innovation and direction, leading to a "sell" rating. Despite being forewarned, Wall Street ...

Biogen (BIIB) announced the initiation of dosing in the global clinical study, TRANSCEND. The Phase 3 study will evaluate the efficacy and ...

Biogen has already been making moves for external deals in recent months, including its offer to buy Cambridge’s Sage Therapeutics Inc., which its longtime partner has refused, and its ...